EN IT

Targeting unmet needs in personalized oncology

XEPTAGEN SpA is engaged in the discovery and clinical validation of novel molecular markers for cancer early detection, monitoring, and evaluation of response to therapy.
Our mission is to improve the clinical management of cancer patients by creating innovative diagnostic tools that may allow a personalized treatment.

Latest Product Literature

Biasiolo A, et al. Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as biomarker in liver disease: biological aspects and clinical applications. Biomarkers in Liver Disease. 1-22. 2016.

Biasiolo A, et al. Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. Dig Liver Dis. 48(2):197-202. 2016.

Cardoso H, et al. Avaliação da acuidade dos níveis séricos de SerpinB3 no diagnóstico de carcinoma hepatocelular. Congresso Português de Hepatologia. Porto, Portugal. 2016.
Biasiolo A, et al. New biomarkers for clinical management of hepatitis C virus infected patients. World J Clin Infect Dis. 5(4):59-66. 2015.

Crescenzi M, et al. Analytical Validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma. Anal Methods. 7:629-637. 2015.

Gallotta A, et al. A novel algorithm based on serum SCCA-IgM determination combined with common clinical data improves prediction of histological NASH. Dig Liver Dis. 47S:e226. 2015.


Press Releases

RSS Feed Widget

Youtube

Tweets by Xeptagen